The U.S. Food and Drug Administration has approved Eli Lilly’s Inluriyo-Verzenio combination for the treatment of breast cancer.
The announcement was reported by Investing.com’s Company News feed.
FDA OKs Lilly’s Inluriyo-Verzenio Breast Cancer Combo
The U.S. Food and Drug Administration has granted approval for Eli Lilly’s Inluriyo-Verzenio combination therapy to treat breast cancer.
PA
Priya Anand · Equities & Earnings Desk · 18 Sept 2026 · 18:47 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
